Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VBL Therapeutics has initiated two studies to evaluate the efficacy and safety of VB-111 in advanced cancers.
Subscribe to our email newsletter
The first, a Phase 2a study, will evaluate VB-111 in patients with advanced differentiated thyroid cancer (DTC), while the second trial, a Phase 1/2 trial, will evaluate VB-111 among patients with relapsed glioblastoma multiforme (GBM).
The Phase 2a study is designed to enroll up to 82 patients with thyroid cancer and will assess the efficacy as well as characterise the safety and tolerability of VB-111 in DTC.
The Phase 1/2 prospective, open-label, single-dose, multi-centre study will enroll patients with relapsed GBM, and will evaluate its effect, as measured by six months of progression-free survival.
The study will also evaluate the bio-distribution of VB-111 in the body, and characterise safety and tolerability of VB-111.
VB-111 is a targeted, dual-action, anti-angiogenic and vascular disruptive agent (VDA) for cancer, which works by cutting off the blood vessels feeding the tumour.